She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Subscribe To Our Newsletter & Stay Updated
